Envoy Medical, Inc.

Envoy Medical, Inc.

NNASDAQ:COCH
6.92
USD
+0.19
(+2.75%)
-2.72EPS
52.58MMarket Cap
Apr 06Next Earn
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.31
0.23
0.26
0.12
0.1
0.03
Basic EPS, GAAP
-10.51
-17.65
-25.43
-14
-12.32
-3.39
Free Cash Flow per Basic Share
-6.95
-8.89
-14.02
-10.07
-7.9
-2.93
Dividend per Share
- -
- -
- -
1.3
0.78
- -
Book Value per Share
-23
-18.51
-0.91
-8.83
-4.07
-0.15
Tangible Book Value per Share
-23
-18.51
-0.91
-8.83
-4.07
-0.15
Basic Weighted Avg Shares
1
1
1
2
2
8
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-2,216.45
-3,673.42
-5,809.81
-8,558.22
-9,240.66
-10,151.52
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-9
-16
-30
-21
-24
-21
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-2,798.39
-6,718.57
-9,468.99
-9,242.22
-9,857.26
-9,026.41
Working Capital
1
-1
- -
1
-5
3
LT Debt
23
34
- -
20
1
1
Total Equity
-45
-36
-2
-19
-12
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
51
61
53

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
28
22
17
Cash, Cash Equivalents & STI
25
20
15
Accounts Receivable, Net
- -
- -
- -
Inventories
1
2
2
Total Current Liabilities
12
13
14
Payables & Accruals
11
12
13
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-37.55%
Free Cash Flow
- -
- -
-2.9%
Net Income, GAAP
- -
- -
14.24%
Sales/Revenue/Turnover
- -
- -
7.11%
Total Cash Common Dividend
- -
- -
0.42%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.9
-2.86
-3.94
-2.83
-14
2025
-2.92
-3.25
-3.55
-2.67
-12.32
2026
-0.83
-0.7
-0.5
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.98
0.29
1.3
2025
0.57
0.28
- -
- -
0.78
2026
- -
- -
- -
- -
- -

Company Description

CEO
Brent T. Lucas
Full Time Employees
43
Sector
Finance
Industry
Financial conglomerates
Address
4875 White Bear Parkway White Bear Lake MN United States 55110
IPO Date
Apr 29, 2021
Business
Envoy Medical, Inc. is a hearing health company specializing in fully implanted hearing devices and medical technologies across the hearing loss spectrum. Its core products include the Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the investigational fully implanted Acclaim® cochlear implant designed for severe to profound sensorineural hearing loss. Additional product offerings encompass bone conduction devices such as auditory osseointegrated implants. The company focuses on leveraging natural ear anatomy with sensor technology to enhance sound capture, aiming to improve access, usability, compliance, and quality of life for patients. Founded in 1995 and headquartered in White Bear Lake, Minnesota, Envoy Medical operates primarily in the U.S. market with ongoing clinical trials and regulatory advancements. Recent strategic developments include the successful elimination of over $32 million in long-term debt, significantly strengthening the company's balance sheet and shareholder equity. Envoy Medical recently secured FDA approval to expand the pivotal clinical trial for the Acclaim cochlear implant to its second and final stage, enrolling additional participants across multiple U.S. sites. The company has enhanced its global patent portfolio with new patents granted in the U.S., Europe, and Australia, reinforcing its leadership in fully implanted hearing technologies. Furthermore, Envoy Medical raised approximately $4 million through a registered direct offering to fund ongoing operations and development efforts. The company also achieved favorable reimbursement strategies for the Esteem implant and continued to focus on scaling commercialization efforts for its technology. Envoy Medical emphasizes innovation within the hearing healthcare industry, targeting adults with various degrees of hearing loss through advanced, fully implanted solutions. This strategic positioning and financial strengthening support Envoy Medical’s goal to expand its market presence and drive adoption of next-generation hearing devices.

Company News

  • Envoy Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

  • Envoy Medical, Inc. (COCH) Reports Q3 Loss, Tops Revenue Estimates

  • Envoy Medical Reports Third Quarter 2026 Results and Highlights Continued Progress

  • Envoy Medical Updates Third Quarter 2026 Earnings Call Time to 8:00 A.M. ET on Thursday, November 5th

  • Envoy Medical to Report Third Quarter 2026 Financial Results on Thursday, November 5th

  • Envoy Medical Announces Reverse Stock Split

  • Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device Design

  • Envoy Medical Submits Second Module of Modular Premarket Approval Application to FDA for Breakthrough Designated Acclaim(R) Cochlear Implant

  • Envoy Medical Announces New Patents, Further Expanding Global Patent Portfolio

  • Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th

  • Envoy Medical (NASDAQ:COCH) vs. American Bio Medica (OTCMKTS:ABMC) Critical Review

  • Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates

  • Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones

  • Envoy Medical, Inc. (COCH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

  • Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial

  • Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant

  • Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device

  • Envoy Medical Terminates At-the-Market (ATM) Equity Facility

  • Envoy Medical to Present at Investor Conferences on June 25th

  • Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th